鮑曼不動桿菌 的英文怎麼說
中文拼音 [bāomànbùdònggǎnjūn]
鮑曼不動桿菌
英文
a. baumannii-
Conclusion acinetobacter baumannii was the major pathogens in ni at present, resistance to antimicrobial agents have the characteristics of high prevalence and multiple resistance, which should be paid attention during clinical process
結論鮑曼不動桿菌是目前醫院感染重要的條件致病菌，其耐藥率呈逐步升高趨勢，且多重耐藥率高，應引起臨床重視。Results the isolation rate of acinetobacter baumannii was the highest in intensive care units ( 31. 66 % ), the next was department of transplantation ( 23. 24 % ) ; respiratory tract and surgical incisional wound were the main infection sites, the infection rate was 49. 91 % and 40. 82 % respectively ; the bacterial resistancet rate to twelve antimicrobial agents ( amikacin, cefoperazone and etc ) increased every year
結果鮑曼不動桿菌檢出科室分佈以重癥監護病房構成比最高，為31 . 66 % ，其次為移植科23 . 24 % ；感染部位以呼吸道和手術切口為主，分別佔49 . 91 %和40 . 82 % 。Methods four hundred and thirty - nine strains of acinetobacter baumannii were isolated from clinical specimens between 2001 and 2004, antimicrobial susceptibility test results were retrospectively analyzed
方法對2001 - 2004年間某院臨床送檢標本中分離的439株鮑曼不動桿菌的分佈及藥敏結果進行回顧性分析。A. baumanii ; was resistant to - lactams ( except imipenem ), with drug resistance rate above 60 %
鮑曼不動桿菌對-內酰胺類抗生素交叉耐藥嚴重，除亞胺培南外，其他藥物耐藥率均高於60 % 。Study on risk factors and molecular typing of acinetobacter baummanii in nosocomial infections
鮑曼不動桿菌醫院感染的危險因素及基因分型研究Objective to realize the prevalence of acinetobacter baumannii in nosocomial infection ( ni ) and its characteristics of antimicrobial susceptibility, and provide evidence for clinical anti - infection treatment
摘要目的了解鮑曼不動桿菌在醫院感染中的流行及藥敏特徵，為臨床抗感染治療提供依據。Conclusion with the increasing rate of isolation in a. baumanii, its drug resistance increases simultaneously
結論鮑曼不動桿菌在臨床的分離率逐年增加，耐藥性逐漸增強，應引起重視。Objective to monitor the characteristics of distribution and drug resistance of a. baumanii in our hospital
摘要目的監測我院近年臨床標本鮑曼不動桿菌的分佈特點及其耐藥情況，以指導臨床合理用藥。Methods a. baumanii separated from clinical samples were tested by k - b for drug susceptibility and identified according to the new standard of nccls 2001
方法從臨床標本中分離鮑曼不動桿菌，用k - b方法行藥敏試驗，按照美國臨床實驗室標準化委員會（ nccls ） 2001年制定最新規則及標準進行結果判讀。分享友人